Acquisitions and Other Transactions (Other Transactions) (Narrative) (Details) $ / shares in Units, $ in Millions							3 Months Ended		12 Months Ended
	Jan. 08, 2016 USD ($) drugs	Sep. 19, 2015	Jan. 30, 2015 USD ($)	Sep. 25, 2014 USD ($)	Sep. 10, 2014 USD ($)	Jun. 30, 2014 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2015 € / shares	Jul. 23, 2015 shares	Apr. 21, 2015 $ / shares	Dec. 31, 2013 USD ($)
Business Acquisition [Line Items]
Development and sales milestone payments									$ 525.0
Par value, per preferred share | € / shares										€ 0.01
Teva unsolicited, non-binding expression of interest purchase price | $ / shares												$ 82
Preferred shares outstanding | shares											488,388,431
Stock issued during period, foreign requirement for acquisition, percent		25.00%
Other current liabilities							$ 1,841.9	$ 1,434.1	1,841.9
Available-for-sale securities							54.0	28.2	54.0
Goodwill							5,380.1	4,049.3	5,380.1				$ 4,340.5
Preferred Stock
Business Acquisition [Line Items]
Other current liabilities							1.3		1.3
Other companies
Business Acquisition [Line Items]
Acquisition purchase price						$ 50.0
Identified intangible assets						36.7
Goodwill						$ 13.3
Other companies | Product rights and licenses
Business Acquisition [Line Items]
Acquisition purchase price							202.5		360.8
Acquisition related costs							2.5		2.5
Cash paid to acquire asset							10.0
Expected future payment next twelve months							165.0
Expected future payment year two							$ 25.0
Acquired intangible assets, weighted average useful life, in years							5 years
Arixtra
Business Acquisition [Line Items]
Acquisition purchase price					$ 300.0
Cash paid to acquire asset				$ 225.0				$ 37.5	37.5
Arixtra | Product rights and licenses
Business Acquisition [Line Items]
Acquired intangible assets, weighted average useful life, in years					10 years
Momenta | Subsequent Event
Business Acquisition [Line Items]
Number of drugs | drugs	6
Collaborative agreement payment	$ 45.0
Momenta | Subsequent Event | Maximum
Business Acquisition [Line Items]
Development and sales milestone payments	$ 200.0
Theravance Biopharma
Business Acquisition [Line Items]
Collaborative agreement payment									$ 15.0
Available-for-sale securities			$ 30.0
Theravance Biopharma | Maximum
Business Acquisition [Line Items]
Development and sales milestone payments			$ 220.0